Oncology:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      UK-VNCAML-220206. Date of Preparation: November 2022.

      FRONTIERS promotional meetings are fully funded and organised by AbbVie for UK healthcare professionals.

      On demand: Access content from previous meetings

      15th December 2022

      Frontiers webinar was a one hour CPD accredited live webinar focusing on AML management with venetoclax. Please access the recorded footage below.

      Dr Chun Yew Fong 

      AML management with venetoclax: current practice & patient experience

      9th – 10th September 2022

      FRONTIERS was a two-day, CPD accredited, in-person meeting in London. The meeting brought together a UK and international faculty of AML and CLL thought leaders to review emerging data, explore practical management and learn about new approaches to service design.

      We invite you to view key presentations from the FRONTIERS meeting. 

      Dr Caroline Alvarez

      Practical management of AML patients with venetoclax

      Dr Paul Cahalin

      Setting up an ambulatory chemotherapy service – the Lancashire experience

      Thomas LeBlanc 

      AML management: reflections on current practice, patient experience and treatment decision-making              

      18th March 2022

      Frontiers: Treating AML in 2022 was a one-day, CPD-accredited meeting for UK HCPs involved in the management of patients with AML. Live presentations and an expert faculty of speakers explored the role of VENCLYXO in AML. We invite you to view key presentations from FRONTIERS 2022.

      Professor Andrew Wei

      The AML treatment landscape

      Discussion on the AML treatment landscape and the arrival of Ven + AZA.

      Dr Dominic Culligan, Dr Priyanka Mehta and Dr Richard Dillon

      Navigating the therapeutic pathway in patients with newly diagnosed AML

      Insights on patient diagnosis and identifying the appropriate treatment for each patient.

      Dr Vidhya Murthy, Sumi Gabriel and Katie Higgins

      Optimising the treatment journey with Ven + AZA in patients with newly diagnosed AML

      A multi-disciplinary panel discuss the key role of the MDT in achieving the best possible outcomes for patients with AML.

      Dr Caroline Alvares, Dr Paul Cahalin and Dr Harpreet Kaur

      The way forward: models of care

      Presenters share models of care and best practice

      Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy1

      References

      1. VENCLYXTO Summary of Product Characteristics.
      VENCLYXTO AML PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected]

      UK-VNCAML-220254. Date of preparation: February 2023.